News | News By Subject | News by Disease News By Date | Search News

HIV/AIDS News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
High School Students "Punched" Martin Shkreli in the Face by Recreating $750 HIV Pill for a Mere $2     12/2/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne     9/20/2016
GlaxoSmithKline (GSK) Execs Set High Hopes for Game-Changing HIV Research Strategy     8/29/2016
Gilead (GILD)'s Odefsey Successful in Two Phase IIIb Studies     7/22/2016
Theratechnologies (TH.TO) Says 82.5% of Patients Achieved Primary Endpoint in Phase III Ibalizumab Trial     5/24/2016
FDA Approves Gilead (GILD)'s Next-Generation HIV Drug Descovy     4/5/2016
FDA Green Lights Gilead (GILD)’s Odefsey to Treat HIV-1 Infection in Certain Patients     3/2/2016
GlaxoSmithKline (GSK) Does Late Holiday Shopping, Buys Two HIV Asset Programs from Bristol-Myers Squibb (BMY) For Up to $2 Billion     12/18/2015
ViiV Healthcare Hitting Hard But Gilead (GILD) Management is Well-Prepared     11/4/2015
Imprimis (immy) Offers $1 Alternative to Turing Pharma's $750 AIDS Drug     10/23/2015
Gilead (GILD)'s New HIV Drug Genvoya Shows Lower Side-Effects Over Longer Term in Two Late-Stage Studies     10/22/2015
Turing Pharma Not Justified in Increasing Daraprim Price by 5,000 Percent, BioSpace Readers Say     9/25/2015
Turing Pharma Becomes Political Football, Donald Trump Weighs In     9/25/2015
Outcry Forces Turing Pharma to Reduce Price Increase of Toxoplasmosis Drug     9/24/2015
GlaxoSmithKline (GSK)'s ViiV Healthcare Successful But Heat From Gilead (GILD) May Be Its Downfall     7/9/2015

News from Around the Web
MRI Scans Can Help Spot HIV In The Brain, University College London Reveals     3/13/2017
Gilead (GILD): Buy The HIV Franchise And Get The Rest For Almost Free     2/28/2017
Cheap Ultrasensitive HIV Sensor To Help Screen Virus In Poorer Places, Instituto de Microelectrónica de Madrid Reveals     2/23/2017
Antiretroviral Therapy May Lead To Syphilis In HIV-Positive Men, Johns Hopkins University School of Medicine Study     1/20/2017
Massive Drop In London HIV Rates May Be Due To Internet Drugs, London School of Hygiene and Tropical Medicine Study     1/11/2017
The GlaxoSmithKline (GSK)-Gilead (GILD) HIV Battle Could Be Epic     12/29/2016
Needle Exchanges, Once Met With Fierce Resistance, Are Working     12/6/2016
Why Can't We Bring Down The Number Of New HIV Cases?     12/1/2016
Injections, Implants Tested As New Weapons To Prevent HIV     11/30/2016
Experimental Vaginal Ring Fights HIV, But Will Women Wear It?     11/16/2016
Imperial College London Scientists Develop New Type Of HIV Test On A USB Stick     11/10/2016
Magic Johnson's HIV Story Offers Hope For Cancer Patients     11/8/2016
HIV Vaccine A Step Closer, The Scripps Research Institute Study     9/13/2016
Is There Anyone The Drug Industry Hates More Than This AIDS Activist?     9/6/2016
First Next-Generation Sequencing Test For HIV Drug Resistance Could Help Combat AIDS Worldwide, Vela Diagnostics Reveals     8/4/2016

Press Releases
GeoVax Labs Inc. (GOVX.OB) Announces Collaboration With American Gene Technologies International For HIV Functional Cure     3/14/2017
MRI Scans Can Help Spot HIV In The Brain, University College London Reveals     3/13/2017
Acuitas Therapeutics Release: Findings Published In Nature Communications Show That Mrna-LNP Encoding A Neutralizing Antibody Protect Humanized Mice From HIV Challenge     3/2/2017
PPD (PPDI) Awarded NIH Contract For HIV Research Support     3/2/2017
Cheap Ultrasensitive HIV Sensor To Help Screen Virus In Poorer Places, Instituto de Microelectrónica de Madrid Reveals     2/23/2017
Data Presented At CROI Show CytoDyn (CYDY)’s Pro 140 As A Single Agent Provided Maximal Virologic Suppression In HIV Patients For Nearly Two Years     2/16/2017
Mologen (MOLGF.PK): New Positive Data On Lefitolimod In HIV     2/16/2017
Gilead (GILD) Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya For Treatment Of HIV-1 In Treatment-Naïve Adults     2/15/2017
Merck & Co. (MRK)’s Doravirine, An Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) For The Treatment Of HIV-1 Infection, Met Primary Efficacy Endpoint In Pivotal Phase III Trial     2/15/2017
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data     2/14/2017
Gilead (GILD) Presents New Phase II Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV     2/14/2017
Gilead (GILD) Announces Findings From New Preclinical Study Evaluating Novel Class Of HIV Capsid Inhibitors     2/14/2017
Two-Year Update From CytoDyn (CYDY)’s PRO 140 Monotherapy Study In HIV To Be Featured In Two Events At CROI 2017     2/14/2017
Phase I Clinical Data Of ABX464, ABIVAX's First-In-Class Anti-HIV Drug, Published In Two Articles In Peer-Reviewed Journals     2/3/2017
GeoVax Labs Inc. (GOVX.OB) Release: Pharma Announces Initiation Of HIV Human Clinical Trial     1/23/2017